Dendreon's New Hurdle: The SEC
by Jon C. Ogg
24/7 Wall St.
It appears that Dendreon (DNDN) may be an SEC target now, or at least it is going to get the pleasure of dealing with the SEC for a while. The New York regional office of the Securities and Exchange Commission has sent a letter as an informal inquiry to Dendreon management. The letter asks for information related to Dendreon's clinical trials for Provenge, its biologics license application for Provenge filed with the FDA, the FDA's review of Provenge, and related correspondence from January 1, 2007 through the present.
The SEC's letter notes that the request should not be construed as any indication by the SEC or its staff that a violation of the federal securities laws has occurred nor should it be considered a reflection upon any person, entity or security,according to the filing.
Continue article at 247WallSt.com
RELATED READING:
- Dendreon Look Out! Swiss Biotech Gains Cancer Vaccine Approval
- Dendreon: Media's Hype and Hope!
- Dendreon Deservingly Jumps on New Cancer Vaccine Report
24/7 Wall St. is a regular contributor to BioHealth Investor
_______________
24/7 Wall St.

The SEC's letter notes that the request should not be construed as any indication by the SEC or its staff that a violation of the federal securities laws has occurred nor should it be considered a reflection upon any person, entity or security,according to the filing.
Continue article at 247WallSt.com
RELATED READING:
- Dendreon Look Out! Swiss Biotech Gains Cancer Vaccine Approval
- Dendreon: Media's Hype and Hope!
- Dendreon Deservingly Jumps on New Cancer Vaccine Report
24/7 Wall St. is a regular contributor to BioHealth Investor
_______________
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home